

AS04-like Adjuvant Systems - Development and Commercialization

Valens™ T4AH: development toward an AS04-like adjuvant system

SPI Pharma is partnered with Inimmune Corp to commercialize an AS04-like adjuvant system.



Valens™ T4AH adjuvant system is an AS04-like adjuvant system combining Inimmune's novel synthetic TLR4 agonist INI-2002 with alum adjuvants from SPI Pharma. SPI Pharma alum and combinations with INI-2002 offer advantages over current clinical adjuvants. Some of those advantages include improved availability, stability, and production sustainability. INI-2002 alone offers greatly improved stability compared to current clinical TLR4 adjuvants.

In July 2024, SPI Pharma and Inimmune Corp announced a partnership to develop and commercialize this adjuvant system.

Efficacy in Pre-Clinical Models

- T4AH demonstrates comparable or improved immunogenicity compared to current clinical TLR4 + alum adjuvant combinations.
- Strong antibody response; Th1 T cell responses can be generated depending on the antigen that is being investigated.
- Our research demonstrates that T4AH is particularly effective in increasing immune responses to poorly immunogenic antigens.

cGMP Manufacturing

- INI-2002 has been manufactured under cGMP conditions.
- SPI Pharma manufactures Alum adjuvants under cGMP conditions.
- T4AH cGMP manufacturing is in progress.

SPI Pharma, as the commercial partner, can assist you with Inimmune's expertise to help develop vaccines readily and easily from our T4AH platform. Please contact SPI Pharma to discuss your needs further, including T4AH samples and relevant data.

www.spipharma.com • salesinfo@spipharma.com



All information and statements given in this brochure are believed to be accurate at the time of publication. However, neither SPI Pharma nor any of their affiliates make any representations or warranty with respect thereto, including, but not limit to, any results obtained in the processing of the products by customers or any third party. All information and statements are intended for persons having the required skill and know-how and do not relieve the customer or user from verifying the suitability of information and statements given for a specific purpose prior to use of products. It is entirely the obligation of the customer or user to comply with applicable laws and regulations, and also with all patent or other intellectual property rights of third parties.